ArticleCardiology2026
The Influence of Left Ventricular Ejection Fraction on Long-Term Survival of Patients after Transcatheter Edge-to-Edge Mitral Valve Repair.
Article in Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTranscatheter edge-to-edge repair (M-TEER) has emerged as an effective treatment for high-risk patients suffering from mitral regurgitation (MR), alleviating symptoms and improving outcomes. However, the prognostic relevance of left ventricular ejection fraction (LVEF) in this population remains unclear.
methodsWe analyzed data from 821 patients undergoing M-TEER at four German tertiary care centers between 2011 and 2022. Patients were stratified into heart failure subgroups based on LVEF: heart failure with preserved ejection fraction (HFpEF, LVEF ≥50%), mildly reduced ejection fraction (HFmrEF, LVEF 41-49%), and reduced ejection fraction (HFrEF, LVEF ≤40%). Propensity score matching was used to balance baseline characteristics. The primary endpoint was all-cause mortality, with secondary endpoints including cardiovascular mortality and major adverse cardiac and cerebrovascular events (MACCE).
resultsHFrEF patients exhibited greater comorbid burden, including higher rates of coronary artery disease and functional MR. Despite these differences, no significant association was observed between LVEF and long-term mortality, even after propensity score matching. Long-term survival rates at 3 years were similar across subgroups: 50.8% for HFrEF, 60.6% for HFmrEF, and 58.9% for HFpEF (p = 0.2). Patients with HFrEF experienced higher in-hospital mortality (5.2%) than HFmrEF (0%) and HFpEF (2.5%), primarily due to non-cardiac causes. The overall rate of MACCE was low at 3.8% (31/821) without significant difference between the respective subgroups. Multivariable analysis identified high-grade tricuspid regurgitation, chronic obstructive pulmonary disease, and impaired renal function as stronger predictors of mortality than LVEF.
conclusionLVEF demonstrated limited prognostic value for long-term outcomes following M-TEER, challenging its role as a standalone marker in this population. Procedural safety and efficacy were consistent across subgroups, underscoring the viability of M-TEER in surgically inoperable patients. Given the significant higher in-hospital mortality rate due to non-cardiac causes in the HFrEF subgroup, tailored therapeutic strategies addressing the underlying diseases should be pursued to optimize outcomes. Future studies should explore possible improvements in risk assessment and patient selection, for example, by integrating emerging imaging modalities and accounting for comorbidities, to improve treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.